Introduction
============

The physiological mechanisms in regulation of gastric emptying (GE) are complex. Basically, stomach delivery or GE involves antral contraction, pyloric relaxation and finally duodenal accommodation to accept the coming luminal contents.[@B1] Apart from myogenic ability to provide motor power, both neural and humoral mechanisms in the high levels are essential in modulating GE.[@B2] Even sexual hormones have been the mediators in controlling gastric motility. For example, estrogen inhibits GE of ovariectomized rats, whereas progesterone enhances their GE.[@B3] Similar to oxytocin, prolactin (PRL) is one of the pituitary gland secretagogues which is mainly inhibited by the hypothalamic dopamine.[@B4] Apart from breast tissue, PRL receptors are also identified in the gastrointestinal (GI) tract. Perhaps PRL mainly coordinates the metabolism, growth and cellular differentiation of GI tract.[@B5] Likewise, we have observed the higher the blood PRL level in the lactated female rats the rapid the GE of these animals, while the small intestinal lengths of lactating rats correlated well with their blood PRL levels.[@B6] Cholecystokinin (CCK) is a famous gut peptide to display the physiological functions in terms of stimulation of pancreatic enzyme secretion, gall bladder contraction, inhibited GE and bowel motility leading to the suppressed food intake and even the regulation of other gut hormones, eg insulin, glucagon and pancreatic polypeptide.[@B7]-[@B9] It is also involved in the hypothalamic-pituitary-adrenal axis since CCK active form releases PRL and vasopressin in animals and humans.[@B10] It probably means the closed interaction of CCK and PRL. We have demonstrated that oxytocin inhibited male/female rat GE is likely activated via a mechanism involving CCK stimulation on one of its receptors, the CCK1.[@B11] Besides, an in vitro study also pointed out that oxytocin inhibited duodenal longitudinal muscle contraction via the CCK release from myenteric plexus neurons.[@B12] We are interested to know whether CCK may also be involved in the PRL mediated GI motility. Using the acute and chronic hyperprolactinemic animal models, the purpose of present study was attempted to elucidate whether the regulation of PRL on rat GE is also mediated via CCK pathway.

Materials and Methods
=====================

Animals and Gastric Emptying Study
----------------------------------

Adult Sprague-Dawley male rats, 3-4 months old, weighing 300-400 g, were obtained from the Animal Center of National Yang-Ming University. The protocol was approved by the Institutional Animal Care and Use Committee of National Yang-Ming University. All the animals were cared in compliance with the Principles of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals published by the National Science Council, Republic of China. They were housed under the controlled conditions of light (06:00-20:00), humidity and temperature (22 ± 1℃). Standard laboratory chow and water were available *ad libitum*. Liquid GE was the representation of present GI motility study. It measured the propulsion of a non-absorbable marker within the gut after an orogastric instillation. Briefly, the feeding procedure was achieved with a temporarily placed orogastric catheter (ID: 1.67 mm, OD: 2.42 mm, PE-205; Clay-Adams, Parsippany, NJ, USA). The motility marker of this nutrient-free liquid was Na^51^CrO~4~ (Dupont, NEN Research Products, Boston, MA, USA) with a radioactivity of 0.5 mCi/mL. All the studied rats were kept in the conscious state and the feeding amount of radiochromium was adjusted to 3 mL/kg. Then the animals were instantly sacrificed with a guillotine 15 minutes later after the successful feeding. Blood was collected to measure plasma CCK levels while the entire stomach and small intestine were carefully removed. The radioactivities of divided stomach and small intestinal segments were measured using a gammacounter (1277 GammaMaster, Pharmacia, Turku, Finland). GE is the percentage of small intestinal radioactivity divided by the total radioactivity recovered from entire stomach plus small intestine.[@B13]

Induction of Hyperprolactinemia
-------------------------------

Acute hyperprolactinemia was induced by the intraperitoneal (i.p.) injection of ovine PRL (oPRL, Sigma, St. Louis, MO, USA) in the doses of 0.5 (n = 6), 1 (n = 6) and 2 mg/kg (n = 6), respectively, 15 minutes before the motility study. This peptide was diluted using the vehicle of deionized water, while control rats (n = 6) only received vehicle injection. On the other hand, the induction of chronic hyperprolactinemia was followed in accordance with the original of Everett and ours.[@B14],[@B15] Briefly, an incision was made in the rat left flank to expose left kidney under the light ether anesthesia. A slit in the renal capsule was made in the graft rat to receive an implantation of 2 anterior pituitary glands (AP, n = 10) in the space beneath. Control rats only received the similar amount of brain cortex (CX, n = 10) under the similar surgery. Liquid GE study was conducted 6 weeks later following either AP or CX graft surgery accordingly.

Lorglumide Blocking Study
-------------------------

Another new group of acute hyperprolactinemic rat model underwent CCK blocking study using the combined i.p. administration of oPRL and lorglumide, a very specific CCK1 receptor antagonist.[@B16] Lorglumide sodium (Research Biochemicals International Co., Natick, MA, USA) was diluted using the vehicle of deionized water. The combined treatment was administered 15 minutes before GE measurement using lorglumide dose in accordance with our previous studies.[@B11],[@B16] Lorglumide blocked rats were divided into 4 groups to receive the regimens: oPRL-vehicle plus lorglumide-vehicle (n = 7), oPRL-vehicle plus lorglumide 10 mg/kg (n = 7), oPRL 1 mg/kg plus lorglumide-vehicle (n = 7) and oPRL 1 mg/kg plus lorglumide 10 mg/kg (n = 7), respectively.

Plasma Processing
-----------------

After the decapitation, rat blood samples were collected and mixed with EDTA (1 mg/mL of blood) and aprotinin (5 TIU/mL of blood). Plasma was immediately obtained by a centrifugation at 1,000 g for 30 minutes at 4℃, then the samples were acidified with an equal volume of 1% trifluoroacetic acid (Buffer A) and then centrifuged at 2,600 g for 20 minutes at 4℃. A SEP-PAK C18 cartridge (Waters Associates, Milford, MA, USA) was equilibrated by 60% acetonitrile in 1% TFA (1 mL, Buffer B) and followed by Buffer A (3 mL, 3 times). The plasma solution was loaded onto the pretreated C18 cartridge. After application of plasma the cartridge was slowly washed with 3 mL Buffer A twice and the peptide slowly eluted with 3 mL Buffer B. The eluant was collected and evaporated in a speed vacuum concentrator (Salvant Instruments, Farmingdale, NY, USA). The dried samples were maintained at -80℃ and subsequently reconstituted with an assay buffer before radioimmunoassay (RIA).

Plasma Cholecystokinin (CCK) Analysis
-------------------------------------

The CCK level in the extracted sample was measured using the similar homemade RIA we had measured previously.[@B11] Briefly, a known amount of unlabeled CCK adjusted to a total volume of 0.3 mL by 0.1% gelatin-phosphate buffer saline was incubated with 0.1 mL of CCK antiserum (1:2,000) which was diluted with normal rabbit serum and 100 mL of \[^3^H\] CCK (\~8,000 cpm; Amersham, Bucks, UK) at 4℃ for 24 hours. Triplicate standard curves with 6 points ranging from 1 to 1,000 pg were included in each assay, while unknown samples were assayed in one sample. A total of 200 mL anti-rabbit-gamma-globulin was then added with further incubation at 4℃ for 24 hours. At the end of incubation the assay tubes were centrifuged at 1,000 g for 20 minutes. The pellet was mixed with 400 mL 1 N NaOH and 80 mL 5 N HCl. The mixture was then mixed with 3 mL of liquid scintillation fluid (Wallac 1409; Pharmacia, Turku, Finland) before the radioactivity was counted in an automatic counter. The measured sensitivity was 8 pg per assay tube. The intra- and inter-assay coefficients of variation were 3% and 5%, respectively.

Statistical Methods
-------------------

All values were expressed as mean ± SE. Numerical data were analyzed using a one-way analysis of variance (ANOVA) with Dunnett\'s post test. A *P*-value of less than 0.05 was considered significant.

Results
=======

Among the acute hyperprolactinemic model, the measured GE of rats receiving vehicle treatment which served as control was 70.6% ± 3.0%, while the GEs of rats receiving 0.5 and 1.0 mg/kg oPRL treatments were 57.2% ± 5.1% and 59.3% ± 6.3%, respectively (NS). However, the GE (42.1% ± 6.6%) of rats with highest dose (2.0 mg/kg) of oPRL treatment displayed significant inhibition compared to vehicle treatment (*P* \< 0.05, [Fig. 1A](#F1){ref-type="fig"}). Meanwhile, the RIA measured plasma CCK level of rats receiving vehicle treatment was 33.8 ± 5.7 pg/mL, while the plasma CCK level of rats receiving low dose (0.5 mg/kg) of oPRL treatment was 42.4 ± 5.5 pg/mL (NS). On the other hand, the rats under higher doses (1.0 and 2.0 mg/kg) of oPRL treatments showed elevated CCK levels compared to vehicle treated rats as 58.5 ± 9.4 pg/mL and 72.4 ± 11.1 pg/mL, respectively (*P* \< 0.05 and 0.01, [Fig. 1B](#F1){ref-type="fig"}). With regard to the chronic hyperprolactinemic model, the measured GE of CX-grafted rats which served as control was 70.5% ± 1.7%, whereas this of AP-grafted rats was significantly inhibited to 54.5% ± 4.7% (*P* \< 0.05, [Fig. 2A](#F2){ref-type="fig"}). The RIA measured plasma CCK level of CX-grafted control rats was 35.8 ± 5.1 pg/mL, while AP-graft markedly elevated plasma CCK level to 48.5 ± 6.3 pg/mL in comparison with control rats (*P* \< 0.05, [Fig. 2B](#F2){ref-type="fig"}). Among the CCK blocking study based on dual oPRL and lorglumide treatment, the rats receiving oPRL-vehicle plus lorglumide-vehicle were served as controls showing a GE value of 68.8% ± 3.0%. Lorglumide itself did not have any effect on rat GE (66.7% ± 3.9%). Treatment of oPRL in the absence of lorglumide again markedly inhibited GE to 45.3% ± 7.5% (*P* \< 0.05). However, this kind of inhibited GE was restored up to 71.8% ± 4.3% when lorglumide was concomitantly administrated with oPRL treatment ([Fig. 3](#F3){ref-type="fig"}).

Discussion
==========

Our study mainly observed that experimentally induced hyperprolactinemic male rats had delayed GE, irrespective of acute oPRL i.p treatment or chronic AP-graft. Although the current study did not simultaneously measure plasma PRL levels in both models, however, our previous studies already confirmed the successful induction of hyperprolactinema with almost 2-fold increase for the male AP-grafted rats.[@B15] Among the acute hyperprolactinemic male rats, we did observe their elevated plasma CCK levels following acute oPRL i.p treatment. In addition, we also demonstrated that AP-graft effectively elevated plasma CCK level compared to CX-grafted rats. Accordingly, the elevated plasma CCK level as well as its delayed GE is likely resulted from the hyperprolactinemic induction, irrespectively of acute oPRL i.p. induction or chronic AP-graft. It is unknown whether there are certain PRL receptors closely adherent to the CCK producing cells since the endogenous CCK is produced under such acute and chronic PRL treated models, and current study was not designed to resolve this controversy.

Mammalian lactation is associated with physiological changes in terms of enhanced GE, sped intestinal transit and gut hyperplasia in the lactating rodents, while some of these changes have been the direct effect of PRL.[@B6],[@B17],[@B18] Besides, i.p. PRL treatment sped mice GI transit, which suggested the modulation via cholinomimetic pathway.[@B19] Perhaps PRL modulates GE via other pathways among the lactated rats. In contrast, our study pointed out that exogenous PRL treatment inhibited male rat GE as well as those of chronic hyperprolactinemic male rats receiving AP graft. We are uncertain whether the gender or lactation difference may account for these discrepant GE results. Unlike lactating female rats showing enhanced GE, we suggest that PRL inhibits male rat GE probably representing the gender specificity. Similarly, Vijayan and McCann[@B20] pointed out that proglumide, a nonspecific CCK receptor antagonist, diminished PRL concentration of male rats, whereas this decrease was not observed among the ovariectomized female rats. Gender difference might exist with regard to this physiological response. In addition, literature indicated that exogenous CCK or its agonist treatment induced PRL release in healthy men,[@B10] adult male/female sheep,[@B21] prepubertal pigs[@B22] and female/male rats,[@B11],[@B23] and it was likely mediated via vasoactive intestinal polypeptide stimulation particularly in male rats. On the other hand, Karashima et al[@B24] found that intra-ventricularly rather than peripherally injected CCK suppressed PRL release in the male Wistar rats, which was obviously functioning in the hypothalmus. However, Miyake et al[@B25] observed that both CCK and vasoactive intestinal polypeptide were not responsible for the meal induced PRL release in men. Hence the interaction between CCK administration and PRL release remains debatable. These discrepant physiological results are most likely depended upon the various routes of peptide administration, species difference and methods of measurement. Our study found that both acute and chronic hyperprolactinemic male rats had an elevated plasma CCK level. It probably means that both peptides do not exist a bio-feed mechanism each other since neither exogenous nor endogenous PRL inhibits the CCK release, at least among the male rats.

It is well known that CCK inhibits GE leading to the satiety sensation in turn to reduce food intake.[@B9],[@B26] Two CCK receptor subtypes in terms of CCK1 and CCK2 already exist in the tissues. It is believed that CCK1 receptors are most abundant in the peripheral tissues, whereas CCK2 receptors are mainly located in the central nervous system.[@B16] Accordingly, exogenous CCK administration induced satiety and inhibited GE and CCK antagonists to treat various functional GI disorders are usually mediated via blocking CCK1 receptors.[@B27] Our study observed that PRL inhibited GE was associated with elevated plasma CCK level, despite of used models of acute or chronic induction. GE inhibition and plasma CCK elevation were obviously found in the acute oPRL treatment in a dose dependant manner. Lorglumide itself had no role in influencing GE. In addition, its simultaneous administration on the male rats receiving exogenous oPRL treatment restored the inhibited GE. Considering these findings, our results are likely to suggest that PRL delayed GE in male rats was similarly mediated via activated CCK through its peripheral CCK1 receptor pathway as well as the inhibitory ability of oxytocin on rat GE.[@B11] Because we did not conduct the blocking of central CCK2 receptor pathway, current study could not resolve whether PRL may additionally inhibit male rat GE via the central CCK2 receptor pathway. In conclusion, present study observed that peripheral oPRL administration or endogenous PRL release using AP graft inhibited male rat GE and elevated plasma CCK level, while this delayed GE was restored using a specific CCK1 receptor antagonist. Perhaps PRL inhibited male rat GE is mediated via a mechanism of activated CCK through its peripheral CCK1 receptor pathway.
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![Gastric emptying value and plasma cholecystokinin (CCK) level of acute hyperprolactinemic male rats. (A) Radiochromium feeding measured gastric emptying of rats receiving intraperitoneal treatment of ovine prolactin (oPRL), while control rats only received vehicle treatment (▪). Highest dose of oPRL treatment inhibited gastric emptying (^\*^*P* \< 0.05). (B) The radioimmunoassay obtained plasma CCK levels of these rats after oPRL treatment. Higher doses of oPRL elevated plasma CCK levels in a dose dependent manner (^\*^*P* \< 0.05 and ^\*\*^*P* \< 0.01). Bars above columns are SE.](jnm-18-385-g001){#F1}

![Gastric emptying value and plasma cholecystokinin (CCK) level of chronic hyperprolactinemic male rats. (A) Radiochromium feeding measured gastric emptying of rats receiving brain graft surgery. Chronic hyperprolactinemic rats received pituitary gland graft (□), while control rats only received brain cortex tissue graft (▪). Pituitary gland graft inhibited gastric emptying (^\*^*P* \< 0.05). (B) The radioimmunoassay obtained plasma CCK levels of these rats after graft surgery. Pituitary gland graft elevated plasma CCK level (^\*^*P* \< 0.05). Bars above columns are SE.](jnm-18-385-g002){#F2}

![Radiochromium feeding measured gastric emptying of rats receiving intraperitoneal dual treatment of ovine prolactin (oPRL) plus cholecystokinin 1 receptor antagonist-lorglumide. Control rats only received vehicle treatment (▪). The oPRL treatment in the lorglumide-vehicle inhibited gastric emptying (^\*^*P* \< 0.05). This inhibition was restored when lorglumide was concomitantly treated together. Bars above columns are SE.](jnm-18-385-g003){#F3}
